Kelly Blackburn
Chief Tech/Sci/R&D Officer at CERVOMED INC.
Net worth: 341 713 $ as of 2024-04-29
Profile
Kelly Blackburn is currently the Chief Executive Officer & Director at Bach Pharma, Inc. and the Senior Vice President-Clinical Development at CervoMed, Inc. Prior to these roles, Blackburn was the Vice President-Clinical Affairs at aTyr Pharma, Inc. from 2013 to 2016.
Blackburn received an undergraduate degree from the University of New Hampshire, a graduate degree from Quinnipiac College, Inc., and a graduate degree from Cambridge College Lima SRL.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
CERVOMED INC.
0.17% | 2024-01-25 | 13,674 ( 0.17% ) | 341 713 $ | 2024-04-29 |
Kelly Blackburn active positions
| Companies | Position | Start |
|---|---|---|
| CERVOMED INC. | Chief Tech/Sci/R&D Officer | 2023-08-15 |
Bach Pharma, Inc.
 Bach Pharma, Inc. Pharmaceuticals: MajorHealth Technology Bach Pharma, Inc. is a private company dedicated to developing new therapeutics for the treatment of life-threatening neurodegenerative diseases. The company is based in North Andover, MA. Recently, the company has been encouraged by the effects of GVT on COVID-19 and a recent study found the effectiveness of GVT in Gulf War illness. Bach Pharma's GVT has also been featured in a Texas A&M publication. Kelly Blackburn has been the CEO of the company since 2016. | Chief Executive Officer | 2016-07-14 |
Former positions of Kelly Blackburn
| Companies | Position | End |
|---|---|---|
| ATYR PHARMA, INC. | Chief Tech/Sci/R&D Officer | 2016-06-30 |
Training of Kelly Blackburn
| University of New Hampshire | Undergraduate Degree |
| Quinnipiac College, Inc. | Graduate Degree |
| Cambridge College Lima SRL | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| ATYR PHARMA, INC. | Health Technology |
| CERVOMED INC. | Commercial Services |
| Private companies | 1 |
|---|---|
Bach Pharma, Inc.
Bach Pharma, Inc. Pharmaceuticals: MajorHealth Technology Bach Pharma, Inc. is a private company dedicated to developing new therapeutics for the treatment of life-threatening neurodegenerative diseases. The company is based in North Andover, MA. Recently, the company has been encouraged by the effects of GVT on COVID-19 and a recent study found the effectiveness of GVT in Gulf War illness. Bach Pharma's GVT has also been featured in a Texas A&M publication. Kelly Blackburn has been the CEO of the company since 2016. | Health Technology |
- Stock Market
- Insiders
- Kelly Blackburn